For the remaining 4 of 22 patients who received combination therapy and whose IL-6 serum level at baseline was not available, 3 patients had lymphoma and 1 had multiple sclerosis treated with anti-CD20 moAbs. This evidence concerns the gene IL6 and lymphoma.